Organization
Université Paris-Saclay, AP-HP, Hospital Bicêtre, INSERM UMR1184, Department of Rheumatology, Le Kremlin Bicêtre, France
1 abstract
Abstract
ACPA POSITIVITY DETERMINES REMISSION IN PATIENTS WITH RA TREATED WITH IV AND SC ABATACEPT: A POST HOC ANALYSIS OF THE REAL-WORLD OBSERVATIONAL ACTION AND ASCORE STUDIESOrg: Schlosspark-Klinik, University Medicine Berlin, Department of Internal Medicine, Rheumatology, Berlin, Germany, Bristol Myers Squibb, Medical Immunology & Fibrosis, Munich, Germany, Bristol Myers Squibb, MESP France – Market Access, Rueil-Malmaison, France, ARC Amsterdam University Hospitals – VU University Medical & Reade, Department of Rheumatology, Amsterdam, Netherlands, Bristol Myers Squibb, Global Drug Development, Princeton, United States of America,